References
- National Cancer Institute. Common Terminology Criteria for Adverse Events v5.0. p. 25, NCI, NIH, DHHS, 2017
- Rothenberg ML, Eckardt JR, Kuhn JG et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14(4):1128-1135, 1996 https://doi.org/10.1200/JCO.1996.14.4.1128
- Xu RH, Muro K, Morita S et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 19(5):660-671, 2018 https://doi.org/10.1016/S1470-2045(18)30140-2
- Maroun JA, Anthony LB, Blais N et al. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol 14(1):13-20, 2007 https://doi.org/10.3747/co.2007.96
- 허준. 국역증보 동의보감. p. 191, 서울, 남산당, 1998
- Edge SB, Byrd D, Compton C et al. AJCC Cancer Staging Manual 7th Edition. p. 144, New York, Springer, 2010
- Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 32(9):920-924, 1997 https://doi.org/10.3109/00365529709011203
- Richardson G, Dobish R. Chemotherapy induced diarrhea. J Oncol Pharm Pract 3(4):181-198, 2007 https://doi.org/10.1200/JOP.0740501
- Benson AB, Ajani JA, Catalano RB et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22(14):2918-2926, 2004 https://doi.org/10.1200/JCO.2004.04.132
- Muehlbauer PM, Thorpe D, Davis A et al. Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapy- and radiotherapy-induced diarrhea. Clin J Oncol Nurs 13(3):336-341, 2009 https://doi.org/10.1188/09.CJON.336-341
- Wadler S, Benson AB, Engelking C et al. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 16(9):3169-3178, 1998 https://doi.org/10.1200/JCO.1998.16.9.3169
- Upadhyay A, Bodar V, Malekzadegan M et al. Loperamide Induced Life Threatening Ventricular Arrhythmia. Case Rep Cardiol volume 2016, article ID 5040176, 2016 Available from:URL:http://dx.doi.org/10.1155/2016/5040176
- Marraffa JM, Holland MG, Sullivan RW et al. Cardiac conduction disturbance after loperamide abuse. Clin Toxicol (Phila) 52(9):952-957, 2014 https://doi.org/10.3109/15563650.2014.969371
- Mego M, Chovanec J, Vochyanova-Andrezalova I et al. Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study. Complement Ther Med 23(3):356-362, 2015 https://doi.org/10.1016/j.ctim.2015.03.008
- de Jong FA, Kehrer DF, Mathijssen RH et al. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist 11(8):944-954, 2006 https://doi.org/10.1634/theoncologist.11-8-944
- Michael M, Brittain M, Nagai J et al. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. J Clin Oncol 22(21):4410-4417, 2004 https://doi.org/10.1200/JCO.2004.11.125
- Mori K, Kondo T, Kamiyama Y et al. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 51(5):403-406, 2003 https://doi.org/10.1007/s00280-003-0585-0
- Kummar S, Copur MS, Rose M et al. A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer 10(2):85-96, 2011 https://doi.org/10.1016/j.clcc.2011.03.003